Login to Your Account

Cubist's Own CDAD Drug Heads To Phase III After Dificid Launch

By Jennifer Boggs

Friday, September 30, 2011
Fresh off of a better-than-expected launch with Clostridium difficile-associated diarrhea (CDAD) drug Dificid (fidaxomicin), Cubist Pharmaceuticals Inc. disclosed plans to move into pivotal testing with its own CDAD candidate, CB-183,315, in the first half of next year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription